Overview

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the Knee

Status:
Recruiting

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

This study is designed as a 3-year, multicenter, open-label study evaluating the safety, tolerability, and efficacy of intra-articular (IA) Lorecivivint (LOR) in subjects with osteoarthritis of the knee in a real-world setting.

Phase:

Phase 3

Details

Lead Sponsor:

Biosplice Therapeutics, Inc.

Treatments:

Adavivint
Lorecivivint